Efavirenz exposure, alone and in combination with known drugs of abuse, engenders addictive-like bio-behavioural changes in rats

[1]  Dhwanil A. Dalwadi,et al.  Adverse Neuropsychiatric Events and Recreational Use of Efavirenz and Other HIV-1 Antiretroviral Drugs , 2018, Pharmacological Reviews.

[2]  D. Macêdo,et al.  HIV antiretroviral drug Efavirenz induces anxiety‐like and depression‐like behavior in rats: evaluation of neurotransmitter alterations in the striatum , 2017, European journal of pharmacology.

[3]  R. Mizrahi,et al.  Neuroinflammation and Oxidative Stress in Psychosis and Psychosis Risk , 2017, International journal of molecular sciences.

[4]  A. Goodwin.  An intravenous self-administration procedure for assessing the reinforcing effects of hallucinogens in nonhuman primates. , 2016, Journal of pharmacological and toxicological methods.

[5]  A. Belmer,et al.  Contribution of Noradrenaline, Serotonin, and the Basolateral Amygdala to Alcohol Addiction: Implications for Novel Pharmacotherapies for AUDs , 2016 .

[6]  Christina L. Ruby,et al.  Recent Advances in Drug Addiction Research and Clinical Applications , 2016 .

[7]  H. Steinbusch,et al.  Developmental fluoxetine and prenatal stress effects on serotonin, dopamine, and synaptophysin density in the PFC and hippocampus of offspring at weaning. , 2016, Developmental psychobiology.

[8]  Z. Coskun,et al.  Evaluation of Δ9-tetrahydrocannabinol metabolites and oxidative stress in type 2 diabetic rats , 2016, Iranian journal of basic medical sciences.

[9]  P. Robledo,et al.  Cognitive Impairment Induced by Delta9-tetrahydrocannabinol Occurs through Heteromers between Cannabinoid CB1 and Serotonin 5-HT2A Receptors , 2015, PLoS biology.

[10]  G. Rainer,et al.  Activation of cannabinoid system in anterior cingulate cortex and orbitofrontal cortex modulates cost-benefit decision making , 2015, Psychopharmacology.

[11]  K. Berridge,et al.  Pleasure Systems in the Brain , 2015, Neuron.

[12]  B. Harvey,et al.  A Review of Biomarkers in Mood and Psychotic Disorders: A Dissection of Clinical vs. Preclinical Correlates , 2015, Current neuropharmacology.

[13]  P. Kawalec,et al.  Efavirenz-Based Regimens in Antiretroviral-Naive HIV-Infected Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials , 2015, PloS one.

[14]  B. Harvey,et al.  Neurodevelopmental Animal Models Reveal the Convergent Role of Neurotransmitter Systems, Inflammation, and Oxidative Stress as Biomarkers of Schizophrenia: Implications for Novel Drug Development. , 2015, ACS chemical neuroscience.

[15]  M. Taffe,et al.  Cannabidiol fails to reverse hypothermia or locomotor suppression induced by Δ9‐tetrahydrocannabinol in Sprague‐Dawley rats , 2015, British journal of pharmacology.

[16]  M. Bajpai,et al.  Enhanced Oral Bioavailability of Efavirenz by Solid Lipid Nanoparticles: In Vitro Drug Release and Pharmacokinetics Studies , 2014, BioMed research international.

[17]  L. B. Bispo-da-Silva,et al.  The aversive, anxiolytic-like, and verapamil-sensitive psychostimulant effects of pulegone. , 2014, Biological & pharmaceutical bulletin.

[18]  A. Antunes,et al.  The phenolic metabolites of the anti-HIV drug efavirenz: evidence for distinct reactivities upon oxidation with Frémy's salt. , 2014, European journal of medicinal chemistry.

[19]  Javier González-Maeso,et al.  The HIV Antiretroviral Drug Efavirenz has LSD-Like Properties , 2013, Neuropsychopharmacology.

[20]  G. Maartens,et al.  Neuronal toxicity of efavirenz: a systematic review , 2013, Expert opinion on drug safety.

[21]  R. Emsley,et al.  Social isolation rearing induces mitochondrial, immunological, neurochemical and behavioural deficits in rats, and is reversed by clozapine or N-acetyl cysteine , 2013, Brain, Behavior, and Immunity.

[22]  M. Geyer,et al.  Characterization of the head-twitch response induced by hallucinogens in mice , 2013, Psychopharmacology.

[23]  P. Fitzgerald.  Elevated Norepinephrine may be a Unifying Etiological Factor in the Abuse of a Broad Range of Substances: Alcohol, Nicotine, Marijuana, Heroin, Cocaine, and Caffeine , 2013, Substance abuse : research and treatment.

[24]  J. McArthur,et al.  Dendritic Spine Injury Induced by the 8-Hydroxy Metabolite of Efavirenz , 2012, Journal of Pharmacology and Experimental Therapeutics.

[25]  A. Der-Avakian,et al.  The neurobiology of anhedonia and other reward-related deficits , 2012, Trends in Neurosciences.

[26]  C. Winstanley,et al.  Contributions of serotonin in addiction vulnerability , 2011, Neuropharmacology.

[27]  R. Emsley,et al.  Isolation rearing-induced deficits in sensorimotor gating and social interaction in rats are related to cortico-striatal oxidative stress, and reversed by sub-chronic clozapine administration , 2011, European Neuropsychopharmacology.

[28]  Stephen J Iturria,et al.  A method for obtaining randomized block designs in preclinical studies with multiple quantitative blocking variables , 2011, Pharmaceutical statistics.

[29]  R. Gainetdinov,et al.  The Physiology, Signaling, and Pharmacology of Dopamine Receptors , 2011, Pharmacological Reviews.

[30]  I. Cuthill,et al.  Animal Research: Reporting In Vivo Experiments: The ARRIVE Guidelines , 2010, British journal of pharmacology.

[31]  N. Osnaya,et al.  Effects of Marijuana and Diazepam on Lipid Peroxidation, Na^+, K^+ Atpase, and Levels of Glutathione and 5-HTP in rat Brain , 2010, Acta biologica Hungarica.

[32]  M. Reith,et al.  Regulation of the dopamine transporter , 2010, Annals of the New York Academy of Sciences.

[33]  S. Izenwasser,et al.  Differential effects of methamphetamine and cocaine on conditioned place preference and locomotor activity in adult and adolescent male rats , 2009, Behavioural Brain Research.

[34]  H. Emrich,et al.  The Pharmacology of Lysergic Acid Diethylamide: A Review , 2008, CNS neuroscience & therapeutics.

[35]  T. Cunha-Oliveira,et al.  Cellular and molecular mechanisms involved in the neurotoxicity of opioid and psychostimulant drugs , 2008, Brain Research Reviews.

[36]  M. Schwarz,et al.  The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression , 2007, Molecular Psychiatry.

[37]  B. Kosofsky,et al.  Prenatal exposure to cocaine alters the development of conditioned place-preference to cocaine in adult mice , 2007, Pharmacology Biochemistry and Behavior.

[38]  B. Balleine,et al.  The Role of the Dorsal Striatum in Reward and Decision-Making , 2007, The Journal of Neuroscience.

[39]  D. Weinshenker,et al.  Perspective There and Back Again : A Tale of Norepinephrine and Drug Addiction , 2007 .

[40]  Danielle L. Graham,et al.  Differential ability of D1 and D2 dopamine receptor agonists to induce and modulate expression and reinstatement of cocaine place preference in rats , 2007, Psychopharmacology.

[41]  T. Rubino,et al.  Cellular Mechanisms Underlying the Anxiolytic Effect of Low Doses of Peripheral Δ9-Tetrahydrocannabinol in Rats , 2007, Neuropsychopharmacology.

[42]  Joseph P. Huston,et al.  Serotonin and psychostimulant addiction: Focus on 5-HT1A-receptors , 2007, Progress in Neurobiology.

[43]  A. Egerton,et al.  Cannabinoids and prefrontal cortical function: Insights from preclinical studies , 2006, Neuroscience & Biobehavioral Reviews.

[44]  P. Seeman.  Targeting the dopamine D2 receptor in schizophrenia , 2006, Expert opinion on therapeutic targets.

[45]  P. Kenny,et al.  Nicotine Self-Administration Acutely Activates Brain Reward Systems and Induces a Long-Lasting Increase in Reward Sensitivity , 2006, Neuropsychopharmacology.

[46]  S. Cooper,et al.  Dopaminergic control of food choice: Contrasting effects of SKF 38393 and quinpirole on high-palatability food preference in the rat , 2006, Neuropharmacology.

[47]  Dan J Stein,et al.  Cortical/hippocampal monoamines, HPA-axis changes and aversive behavior following stress and restress in an animal model of post-traumatic stress disorder , 2006, Physiology & Behavior.

[48]  J. Girault,et al.  Plasticity-Associated Gene Krox24/Zif268 Is Required for Long-Lasting Behavioral Effects of Cocaine , 2006, The Journal of Neuroscience.

[49]  S. Khoo,et al.  Intracellular and plasma pharmacokinetics of efavirenz in HIV-infected individuals. , 2005, The Journal of antimicrobial chemotherapy.

[50]  B. O'dowd,et al.  Deletion of dopamine D1 and D3 receptors differentially affects spontaneous behaviour and cocaine‐induced locomotor activity, reward and CREB phosphorylation , 2005, The European journal of neuroscience.

[51]  M. Rodríguez-Arias,et al.  Long-lasting rewarding effects of morphine induced by drug primings , 2005, Brain Research.

[52]  E. Rüther,et al.  Anhedonia and motivational deficits in rats: Impact of chronic social stress , 2005, Behavioural Brain Research.

[53]  J. Zwiller,et al.  Acute or repeated cocaine administration generates reactive oxygen species and induces antioxidant enzyme activity in dopaminergic rat brain structures , 2005, Neuropharmacology.

[54]  B. Clotet,et al.  Long-Term Neuropsychiatric Disorders on Efavirenz-Based Approaches: Quality of Life, Psychologic Issues, and Adherence , 2005, Journal of acquired immune deficiency syndromes.

[55]  B. Gosnell.  Sucrose intake enhances behavioral sensitization produced by cocaine , 2005, Brain Research.

[56]  D. Braida,et al.  Δ9-Tetrahydrocannabinol-induced conditioned place preference and intracerebroventricular self-administration in rats , 2004 .

[57]  P. Kalivas,et al.  Brain circuitry and the reinstatement of cocaine-seeking behavior , 2003, Psychopharmacology.

[58]  B. Hoebel,et al.  Amphetamine-sensitized rats show sugar-induced hyperactivity (cross-sensitization) and sugar hyperphagia , 2003, Pharmacology Biochemistry and Behavior.

[59]  Rita Z. Goldstein,et al.  Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex. , 2002, The American journal of psychiatry.

[60]  M. Pistis,et al.  Δ9-Tetrahydrocannabinol decreases extracellular GABA and increases extracellular glutamate and dopamine levels in the rat prefrontal cortex: an in vivo microdialysis study , 2002, Brain Research.

[61]  R. Summers,et al.  Role of adrenoceptor subtypes in memory consolidation , 2002, Progress in Neurobiology.

[62]  R. Paredes,et al.  Quality of Life, Emotional Status, and Adherence of HIV‐1‐Infected Patients Treated With Efavirenz Versus Protease Inhibitor‐Containing Regimens , 2002, Journal of acquired immune deficiency syndromes.

[63]  J. Gatell,et al.  Preliminary Data of a Prospective Study on Neuropsychiatric Side Effects After Initiation of Efavirenz , 2001, Journal of acquired immune deficiency syndromes.

[64]  D. Murphy,et al.  Molecular mechanisms of cocaine reward: Combined dopamine and serotonin transporter knockouts eliminate cocaine place preference , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[65]  T. Tzschentke.  Pharmacology and behavioral pharmacology of the mesocortical dopamine system , 2001, Progress in Neurobiology.

[66]  A. Telenti,et al.  Efavirenz Plasma Levels Can Predict Treatment Failure and Central Nervous System Side Effects in Hiv-1-infected Patients , 2022 .

[67]  R. Bevins,et al.  Conditioned place preference: what does it add to our preclinical understanding of drug reward? , 2000, Psychopharmacology.

[68]  J. Cheer,et al.  Cannabinoid receptors and reward in the rat: a conditioned place preference study , 2000, Psychopharmacology.

[69]  G. Koob.  Neurobiology of Addiction: Toward the Development of New Therapies , 2000, Annals of the New York Academy of Sciences.

[70]  K. Tashima,et al.  Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. , 1999, The New England journal of medicine.

[71]  A. Leshner.  Addiction is a brain disease, and it matters. , 1997, Science.

[72]  T. Reader,et al.  Distribution of indoleamines and [3H]paroxetine binding in rat brain regions following acute or perinatal Δ9-tetrahydrocannabinol treatments , 1993, Neurochemical Research.

[73]  S. O'dell,et al.  Multiple methamphetamine injections induce marked increases in extracellular striatal dopamine which correlate with subsequent neurotoxicity , 1991, Brain Research.

[74]  橘 敏明,et al.  Open-Field Testの妥当性と信頼性 , 1983 .

[75]  H. Meltzer,et al.  Lysergic acid diethylamide: Evidence for stimulation of pituitary dopamine receptors , 1977, Psychopharmacology.

[76]  J. E. Brown,et al.  Kinetic studies of food intake and sucrose solution preference by rats treated with low doses of delta9-tetrahydrocannabinol. , 1977, Behavioral biology.

[77]  E. Wolf,et al.  Efavirenz Causes Oxidative Stress, Endoplasmic Reticulum Stress, and Autophagy in Endothelial Cells , 2015, Cardiovascular Toxicology.

[78]  K. Mokwena.  The Novel Psychoactive Substance NyaopeBrings UniqueChallenges to Mental Health Services in South Africa , 2015 .

[79]  K. Hauser,et al.  Glial modulators as potential treatments of psychostimulant abuse. , 2014, Advances in pharmacology.

[80]  P. Murthy,et al.  Birth Order and Sibling Gender Ratio of a Clinical Sample Chemistry, Metabolism, and Toxicology of Cannabis: Clinical Implications Chemical Components of Cannabis , 2022 .

[81]  Mood and Anxiety Related Phenotypes in Mice , 2011, Neuromethods.

[82]  S. Spijker,et al.  Dissection of Rodent Brain Regions , 2011 .

[83]  Todd D Gould,et al.  Mood and anxiety related phenotypes in mice : characterization using behavioral tests , 2009 .

[84]  A. Goodman.  Neurobiology of addiction. An integrative review. , 2008, Biochemical pharmacology.

[85]  J. Aberg,et al.  Neuropsychiatric Complications of Antiretroviral Therapy , 2006, Drug safety.

[86]  P. Seeman.  Targeting the dopamine D 2 receptor in schizophrenia , 2006 .